Med Device Online Highlights 2026 ISPE Europe Annual Conference Keynote: “Stronger Together: A One Team Mindset to Building a Global Aseptic Manufacturing Network”
During the 2026 ISPE Europe Annual Conference, Syed Abbas Yar‑Khan, Group Vice President, Global Parenteral Products and Devices, Eli Lilly and Company, presented a keynote speech entitled, “Stronger Together: A One Team Mindset to Building a Global Aseptic Manufacturing Network.” In the article that follows, Yar-Khan summarizes his presentation, explaining how Lilly’s global parenteral and device manufacturing strategy is undergoing one of the most ambitious transformations in the pharmaceutical industry, driven by a unified operational mindset and a deeply standardized approach to facility design. Yar-Khan explains how the company is executing a massive expansion while maintaining consistency, agility, and innovation across a network that spans the US, Europe, and Asia.
Lilly’s capital program, totaling $55 billion, includes new parenteral facilities in Germany, Ireland, the Netherlands, and ten sites across the US and Puerto Rico. The company’s philosophy centers on a “one‑team mindset,” which treats every site—regardless of geography or age—as part of a single, harmonized network. This means identical technology platforms, software systems, and operating models across all locations. The goal is not rigid uniformity but disciplined replication: a standard design serves as the baseline, while site‑specific constraints (infrastructure, footprint, modality requirements) guide-controlled deviations. The emphasis is on ensuring that exceptions do not erode the value of the standard.
Contrary to the belief that standardization stifles innovation, Lilly uses its templated design approach to accelerate technology adoption. “We don't freeze technology; we freeze the interfaces,” shared Yar-Khan. This allows new isolators, environmental monitoring sensors, or container‑closure integrity testing methods to be integrated as long as they fit the established automation and data architecture. New technologies are piloted at a single site under a formal readiness framework before being considered for network‑wide rollout. The structured approach allows Lilly to evaluate innovations cleanly and scale them quickly without introducing risk across the network.
A major shift in Lilly’s parenteral operations is the move to a standardized automated filling platform. This has transformed environmental monitoring (EM), enabling harmonized sampling strategies, comparable data across sites, and network‑wide trend analysis. Investigations now benefit from shared data structures and cross‑site applicability of lessons learned. This harmonization supports faster problem‑solving and continuous improvement across the global network.
Lilly relies on structured governance mechanisms to ensure rapid dissemination of insights. Weekly parenteral device network huddles allow sites to surface issues and share learnings in real time. Network‑wide metrics provide transparency into performance, while on‑site business reviews formalize the exchange of best practices across safety, quality, delivery, people, and cost. Personnel mobility—rotating leaders and experts across sites—is a deliberate strategy to prevent blind spots and strengthen cross‑site understanding.
As Lilly advances toward end‑to‑end automation and agentic AI, operator roles are shifting from manual execution to data‑driven decision‑making. Operators now require system awareness, data fluency, and the ability to interpret AI‑generated insights. Agentic AI systems proactively analyze process data and flag potential issues before they escalate, transforming operator roles from monitoring to informed decision‑making.
Upcoming ISPE Conferences
About Med Device Online
Med Device Online is part of the Life Science Connect media group. The publication covers news related to all facets of the medical device industry, including device design, engineering, manufacturing, regulatory affairs, quality, and commercialization.